← Back to Screener
Ligand Pharmaceuticals Inc. (LGND)
Price$223.24
Favorite Metrics
Price vs S&P 500 (26W)18.02%
Price vs S&P 500 (4W)1.61%
Market Capitalization$4.50B
P/E Ratio (Annual)36.12x
All Metrics
P/CF (Annual)91.07x
Book Value / Share (Quarterly)$51.44
P/TBV (Annual)6.26x
Indicated Dividend (Annual)$0.00
Revenue Growth (3Y)10.97%
Cash Flow / Share (Quarterly)$2.47
Price vs S&P 500 (YTD)16.41%
Gross Margin (TTM)94.57%
Net Profit Margin (TTM)46.42%
EPS (TTM)$5.88
10-Day Avg Trading Volume0.27M
EPS Excl Extra (TTM)$5.88
Revenue Growth (5Y)7.54%
EPS (Annual)$6.13
ROI (Annual)8.50%
Gross Margin (Annual)94.57%
Net Profit Margin (5Y Avg)17.46%
Cash / Share (Quarterly)$37.10
P/E Basic Excl Extra (TTM)36.12x
Revenue Growth QoQ (YoY)39.37%
P/E Normalized (Annual)36.12x
ROA (Last FY)7.97%
Revenue Growth TTM (YoY)60.40%
EBITD / Share (TTM)$3.66
ROE (5Y Avg)4.11%
Operating Margin (TTM)15.29%
Cash Flow / Share (Annual)$2.47
P/B Ratio4.42x
P/B Ratio (Quarterly)3.66x
Net Income / Employee (Annual)$3
EV / Revenue (TTM)17.78x
Net Interest Coverage (TTM)3.08x
ROA (TTM)10.18%
EV / EBITDA (TTM)64.74x
EPS Incl Extra (Annual)$6.13
Current Ratio (Annual)22.23x
Quick Ratio (Quarterly)21.98x
3-Month Avg Trading Volume0.23M
52-Week Price Return111.17%
EV / Free Cash Flow (Annual)97.46x
P/E Incl Extra (TTM)36.12x
Revenue / Employee (TTM)$6
Tangible BV / Share (Quarterly)$30.08
P/S Ratio (Annual)16.77x
Asset Turnover (Annual)0.17x
52-Week High$234.76
Operating Margin (5Y Avg)8.09%
EPS Excl Extra (Annual)$6.13
CapEx CAGR (5Y)-36.85%
Tangible BV CAGR (5Y)41.96%
26-Week Price Return22.01%
Quick Ratio (Annual)21.98x
13-Week Price Return8.84%
Total Debt / Equity (Annual)0.44x
Current Ratio (Quarterly)22.23x
Enterprise Value$4,766.415
Revenue / Share Growth (5Y)2.80%
Asset Turnover (TTM)0.22x
Book Value / Share Growth (5Y)3.14%
Revenue / Employee (Annual)$6
Inventory Turnover (Annual)1.25x
Pretax Margin (Annual)59.29%
Cash / Share (Annual)$37.10
3-Month Return Std Dev41.58%
Gross Margin (5Y Avg)86.12%
Net Income / Employee (TTM)$3
EBITDA CAGR (5Y)8.39%
EBITDA Interim CAGR (5Y)1.90%
ROE (Last FY)12.23%
Net Interest Coverage (Annual)-1.87x
EPS Basic Excl Extra (Annual)$6.13
P/FCF (TTM)60.22x
Receivables Turnover (TTM)5.47x
EV / Free Cash Flow (TTM)97.46x
Total Debt / Equity (Quarterly)0.44x
EPS Incl Extra (TTM)$5.88
Receivables Turnover (Annual)5.47x
ROI (TTM)11.10%
P/S Ratio (TTM)16.77x
Pretax Margin (5Y Avg)28.94%
Revenue / Share (Annual)$13.21
Tangible BV / Share (Annual)$30.08
Forward P/E25.85x
Free OCF CAGR (5Y)-0.48%
Price vs S&P 500 (52W)81.34%
P/E Ratio (TTM)36.12x
EPS Growth TTM (YoY)-14.89%
Year-to-Date Return19.05%
5-Day Price Return9.46%
EPS Normalized (Annual)$6.13
ROA (5Y Avg)2.84%
Net Profit Margin (Annual)46.42%
Month-to-Date Return12.74%
Cash Flow / Share (TTM)$4.86
EBITD / Share (Annual)$3.63
Operating Margin (Annual)15.29%
LT Debt / Equity (Annual)0.44x
P/CF (TTM)91.07x
ROI (5Y Avg)3.10%
P/E Excl Extra (TTM)36.12x
LT Debt / Equity (Quarterly)0.44x
EPS Basic Excl Extra (TTM)$5.88
P/TBV (Quarterly)6.26x
P/B Ratio (Annual)3.66x
Inventory Turnover (TTM)1.25x
Pretax Margin (TTM)59.29%
Book Value / Share (Annual)$51.44
Price vs S&P 500 (13W)8.15%
Beta1.58x
P/FCF (Annual)91.91x
Revenue / Share (TTM)$12.97
ROE (TTM)13.86%
52-Week Low$98.89
Analyst Recommendations
Jan 2026
Feb 2026
Mar 2026
Apr 2026
4.29
4.29
4.29
4.33
Industry Peers — Pharmaceuticals(308)
| Symbol | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|
LGNDLigand Pharmaceuticals Inc. | 16.77x | 60.40% | 94.57% | — | $223.24 |
LLYEli Lilly & Co. | 13.08x | 44.70% | 83.04% | 27.59% | $903.99 |
JNJJohnson & Johnson | 5.94x | 7.87% | 67.95% | 14.90% | $234.54 |
ABBVABBVIE INC. | 6.04x | 8.57% | 71.62% | -2.88% | $208.99 |
MRKMerck & Co., Inc. | 4.41x | 1.31% | 78.55% | 21.23% | $115.46 |
AZNAstraZeneca PLC | 5.28x | 8.63% | 81.31% | 21.88% | $200.47 |
NVSNovartis AG | 4.98x | 8.91% | 75.82% | 15.26% | $149.73 |
NVONovo-Nordisk A/S | 3.62x | 6.43% | 80.98% | 20.66% | $40.93 |
ABTAbbott Laboratories | 3.66x | 6.59% | 56.50% | 8.20% | $95.47 |
PFEPfizer Inc. | 2.47x | -1.64% | 75.81% | -3.51% | $27.22 |
BMYBristol-Myers Squibb Co. | 2.47x | -0.22% | 72.63% | — | $58.96 |
About
Ligand Pharmaceuticals is a biopharmaceutical company focused on developing and acquiring drug technologies through strategic partnerships and licensing agreements. The company generates revenue from three primary sources: royalties on commercialized products, licensing and milestone payments, and sales of its proprietary Captisol platform.